Skip to content

To Explore the Accuracy and Effectiveness of a Novel Intraoperative Cellular Probe Technology in Breast-Conserving Surgery for Breast Cancer: A Parallel Controlled Study

To Explore the Accuracy and Effectiveness of a Novel Intraoperative Cellular Probe Technology in Breast-Conserving Surgery for Breast Cancer: A Parallel Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086798
Enrollment
Unknown
Registered
2024-07-11
Start date
2024-07-25
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Experimental Group:ES-Assisted Breast-Conserving Surgery Group (ES Interpretation: Conducted by a breast surgeon and a pathologist, both of whom have received at least one hour of ES training before p
Control Group:Frozen Pathology Interpretation Group
Gold Standard Group:Gold Standard Interpretation: Conducted by a tumor cytology pathologist, using paraffin pathology interpretation as the gold standard.

Sponsors

Nanchang People's Hospital (Nanchang Third Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: a) Age between 18 and 70 years; b) Early-stage breast cancer with tumor size less than 5 cm, c N 0-1; c) No involvement of skin, subcutaneous tissue, pectoralis major muscle, or nipple-areola complex; d) No evidence of distant metastasis on clinical or imaging studies; e) Voluntary signing of informed consent by the participant or exemption from signing after approval by the ethics committee.

Exclusion criteria

Exclusion criteria: a) Inflammatory breast cancer; b) Presence of chest wall or skin involvement, locally advanced breast cancer; c) Extensive axillary lymph node metastasis (stage IIIB and above); d) Severe comorbidities (e.g., organ dysfunction, immunodeficiency) or poor general condition; e) Inability to undergo general anesthesia or surgery; f) Participation in other clinical studies that may interfere with this trial; g) Inability to obtain satisfactory specimens for both intraoperative frozen pathology and paraffin pathology; h) Inability to obtain a paraffin pathology report.

Design outcomes

Primary

MeasureTime frame
Accuracy: Using paraffin pathology as the gold standard, evaluate the sensitivity and specificity of ES detection compared to rapid frozen pathology interpretation;

Secondary

MeasureTime frame
Consistency Rate: Evaluate the consistency between pathologists and clinical doctors in interpreting ES results;Usability Score: Assess the usability and image satisfaction of the ES through questionnaires completed by pathologists and surgeons;Learning Curve Index: Record and analyze the time taken and accuracy of interpretation by surgeons using the ES;

Countries

China

Contacts

Public ContactZhihua Li

Nanchang People's Hospital (Nanchang Third Hospital)

648195859@qq.com+86 150 7005 2282

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026